Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
==== Electrical power grid ==== The federal government of the United States admits that the electric power grid is susceptible to cyberwarfare. The United States Department of Homeland Security works with industries to identify vulnerabilities and to help industries enhance the security of control system networks. The federal government is also working to ensure that security is built in as the next generation of "smart grid" networks are developed. In April 2009, reports surfaced that China and Russia had infiltrated the U.S. electrical grid and left behind software programs that could be used to disrupt the system, according to current and former national security officials. The North American Electric Reliability Corporation (NERC) has issued a public notice that warns that the electrical grid is not adequately protected from cyber attack. China denies intruding into the U.S. electrical grid. One countermeasure would be to disconnect the power grid from the Internet and run the net with droop speed control only. Massive power outages caused by a cyber attack could disrupt the economy, distract from a simultaneous military attack, or create a national trauma. Iranian hackers, possibly Iranian Cyber Army pushed a massive power outage for 12 hours in 44 of 81 provinces of Turkey, impacting 40 million people. Istanbul and Ankara were among the places suffering blackout. Howard Schmidt, former Cyber-Security Coordinator of the US, commented on those possibilities:
== History == In 1811, Bernard Courtois discovered iodine was present in seaweed, and iodine intake was linked with goiter size in 1820 by Jean-Francois Coindet. Gaspard Adolphe Chatin proposed in 1852 that endemic goiter was the result of not enough iodine intake, and Eugen Baumann demonstrated iodine in thyroid tissue in 1896. The first cases of myxedema were recognized in the mid-19th century (the 1870s), but its connection to the thyroid was not discovered until the 1880s when myxedema was observed in people following the removal of the thyroid gland (thyroidectomy). The link was further confirmed in the late 19th century when people and animals who had had their thyroid removed showed improvement in symptoms with transplantation of animal thyroid tissue. The severity of myxedema, and its associated risk of mortality and complications, created interest in discovering effective treatments for hypothyroidism. Transplantation of thyroid tissue demonstrated some efficacy, but recurrences of hypothyroidism was relatively common, and sometimes required multiple repeat transplantations of thyroid tissue. In 1891, the English physician George Redmayne Murray introduced subcutaneously injected sheep thyroid extract, followed shortly after by an oral formulation. Purified thyroxine was introduced in 1914 and in the 1930s synthetic thyroxine became available, although desiccated animal thyroid extract remained widely used. Liothyronine was identified in 1952. Early attempts at titrating therapy for hypothyroidism proved difficult.
The light-nanosecond is defined as exactly 29.9792458 cm. It was popularized in information technology as a unit of distance by Grace Hopper as the distance which a photon could travel in one billionth of a second (roughly 30 cm or one foot): "The speed of light is one foot per nanosecond."
=== Proposed diagnoses === Terminal anorexia nervosa (TAN) is a proposed psychiatric diagnosis and is not currently clinically recognized. It may be used to facilitate access to medical assistance in dying (MAID). Patients may be considered for TAN if they are at least 30 years old, have previously and persistently received "high-quality multidisciplinary eating disorder care", and have clearly and consistently expressed that additional treatment would be futile.
The new 19th district, then as now, encompasses much of West Texas including Lubbock and Abilene along with Big Spring. The incumbent is Republican Jodey Arrington, who was re-elected with 80.7% of the vote in 2024. Arrington is not seeking reelection to a sixth term in the heavily Republican district, which gave 75.3% of the vote to Donald Trump and 73% to Ted Cruz in 2024, and is a majority White district with a voting age population that is 34.7% Hispanic.
Sources: en.wikipedia.org
=== Intravenous administration === Many forms of medication (from antibiotics to chemotherapy) are administered intravenously, as they are not readily or adequately absorbed by the digestive tract. After severe acute blood loss, liquid preparations, generically known as plasma expanders, can be given intravenously, either solutions of salts (NaCl, KCl, CaCl2 etc.) at physiological concentrations, or colloidal solutions, such as dextrans, human serum albumin, or fresh frozen plasma. In these emergency situations, a plasma expander is a more effective life-saving procedure than a blood transfusion, because the metabolism of transfused red blood cells does not restart immediately after a transfusion.
== History == Atractylosides have been used as poisons since at least 100 AD, though it was not isolated and characterized until 1868 by LeFranc, after extracting it from Atractylis gummifera. After high-profile accidental poisonings—children in Italy and Algeria ate parts of the plant in 1955 and 1975, respectively—renewed interest in atractyloside resulted in future research. Historically, the ATR plant sources have been used for numerous reasons: whether for its therapeutic properties, magico-religious purposes, or its toxicity. While its therapeutic uses may be due to the coincidental presence of other compounds, some uses of ATR-containing plants include treating sinusitis, headaches, syphilitic ulcers, and whitening teeth among other applications. Separately, the Atractylis gummifera is a traditional herb used in North Africa while Callilepis laureola is well known to the Zulu people in South Africa for both therapeutical applications and its spiritual context to ward away evil spirits. When in high dosages, ATR's toxicity has been utilized for suicide and murder, though there have been no especially high-profile incidents reported, at least somewhat due to difficulties identifying ATR poisoning. More commonly than suicide or murder, ATR is a result of accidental poisoning: livestock grazing can poison animals, while an unintended overdose or exposure of a plant containing ATR can poison humans. Particularly, the Atractylis gummifera is easily confused with wild artichoke and other vegetables, and its sweet-tasting roots facilitate its consumption.
Humankind gradually evolved from early members of the genus Homo—such as Homo habilis, who used simple stone tools—into anatomically modern humans as well as behaviourally modern humans by the Upper Paleolithic. During the end of the Paleolithic Age, specifically the Middle or Upper Paleolithic Age, humans began to produce the earliest works of art and to engage in religious or spiritual behavior such as burial and ritual. Conditions during the Paleolithic Age went through a set of glacial and interglacial periods in which the climate periodically fluctuated between warm and cool temperatures. By c. 50,000 – c. 40,000 BP, the first humans set foot in Australia. By c. 45,000 BP, humans lived at 61°N latitude in Europe. By c. 30,000 BP, Japan was reached, and by c. 27,000 BP humans were present in Siberia, above the Arctic Circle. By the end of the Upper Paleolithic Age humans had crossed Beringia and expanded throughout the Americas continents.
=== Christmas Island and the B.P.C. === Following the Nauru Agreement of 2 July 1919 the interests of the PPC in the phosphate deposits in Nauru and Ocean Island were acquired by the governments of the United Kingdom, Australia and New Zealand, which carried out mining under the direction of the Board of Commissioners, which represented the three governments.
=== Pharmacodynamics === Both THC and CBN activate the CB1 (Ki = 211.2 nM) and CB2 (Ki = 126.4 nM) receptors. Each compound acts as a low affinity partial agonist at CB1 receptors with THC demonstrating 5x–10× greater affinity to the CB1 receptor. Like THC, CBN has a higher selectivity for CB2 receptors which are located throughout the central and peripheral nervous system, but are primarily associated with immune function. CB2 receptors are known to be located on immune cells throughout the body, including macrophages, T cells, and B cells. These immune cells have been shown to decrease production of immune-related chemical signals (e.g., cytokines) or undergo apoptosis as a consequence of CB2 agonism by CBN. In cell culture, CBN demonstrates antimicrobial effects, particularly in instances of antibiotic-resistant bacteria. CBN has also been reported to act as an ANKTM1 channel agonist at high concentrations (>20nM). While some phytocannabinoids have been shown to interact with nociceptive and immune-related signaling via transient receptor potential channels (e.g., TRPV1 and TRPM8), there is currently limited evidence to suggest that CBN acts in this way. In preclinical rodent studies, CBN, anandamide and other CB1 agonists have demonstrated inhibitory effects on GI motility, reversible via CB1R blockade (i.e., antagonism). In considering the efficacy of cannabis-based products, there remains controversy surrounding a concept termed “the entourage effect”.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.